Use of Anti-IL-5 Pathway Therapies for Eosinophilic Diseases
Saturday, March 4, 2017: 6:30 AM-7:30 AM
Hyatt Regency Atlanta, Atlanta Conference Level (LL3), Dunwoody
1.00 CME/CE

Learning Objectives:
  1. List the anti-IL-5 pathway therapies that have FDA-approved and are in development
  2. Discuss the data supporting use of anti-IL-5 pathway therapies in the treatment of severe asthma
  3. Discuss the clinical trial data for use of the anti-IL-5 pathway therapies in other eosinophilic diseases including hypereosinophilic syndrome, nasal polyposis, and eosinophilic esophagitis
Discussion Leader
Princess U. Ogbogu, MD FAAAAI
Discussion Leader
Sameer K. Mathur, MD PhD FAAAAI
See more of: Session